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 Two-year drug survival of dupilumab in a large cohort of 
difficult-to-treat adult atopic dermatitis patients compared to 
cyclosporine A and methotrexate: Results from the BioDay 
registry 
 To the Editor, 
 Dupilumab is a fully human monoclonal antibody that targets the 
interleukin (IL)-4 receptor subunit α (IL-4 Rα), the common subunit 
of the type 2 cytokines IL-4 and IL-13, blocking signaling of both cy-
tokines and consequently inhibiting the entire Th2 pathway. 1 Overall, 
the clinical efficacy and safety of dupilumab ± topical corticosteroids 
 DOI: 10.1111/all.14324 
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(TCS) have been demonstrated in several phase 3 clinical trials for 
the treatment of patients with moderate-to-severe AD. 2 In clinical 
trials, efficacy of dupilumab is tested under ideal circumstances in 
selected patients, and therefore, results are not always generaliz-
able to daily practice. Recent results from dupilumab treatment in 
daily practice show a clinically relevant improvement of physician-
reported outcome measures and patient-reported outcome meas-
ures after 3-6 months, which is in line with data from clinical trials. 3,4 
 Drug survival is an analysis which gives a reflection of daily 
practice by analyzing the time from initiation to discontinuation of 
therapy. Drug survival is a comprehensive outcome covering effec-
tiveness, safety, and patients’ and doctors’ preferences. 5 Drug sur-
vival studies for dupilumab are scarce, and studies comparing drug 
survival of dupilumab with conventional oral immunosuppressive 
drugs for AD are lacking. 6 In the current study, we primarily aim to 
assess the drug survival of dupilumab, and secondarily to compare 
drug survival of dupilumab with other oral immunosuppressive drugs 
(cyclosporine A (CsA) and methotrexate (MTX)) in two historical (pre-
viously published) daily practice cohorts of moderate-to-severe AD 
patients before the introduction of dupilumab. 7,8 Patients treated 
with dupilumab were included in the BioDay registry, a prospective 
multicenter registry that contains daily practice data on the effec-
tiveness and safety of dupilumab for the treatment of AD, including 
both quality of life (QoL) as well as clinical parameters. Patients were 
treated with MTX, CsA, and dupilumab according to national guide-
lines concerning dosage and follow-up. Drug survival was determined 
through Kaplan-Meier survival curves and analyzed for overall drug 
survival (discontinuation due to well-controlled disease; side effects 
[with/without ineffectiveness]; ineffectiveness [with/without side 
effects]; and other) for dupilumab, CsA, and MTX and separately 
for treatment failure (ineffectiveness combined with side effects). 
Patients, who were using dupilumab/CsA/MTX at time of data lock 
or were lost to follow-up, were censored. For each patient, data on 
treatment duration and reason for discontinuation were collected, as 
well as other detailed patient and treatment characteristics. 
 The dupilumab cohort comprised of 402 patients (39.1% female, 
mean age 43.3 years) with a median dupilumab treatment duration 
of 15.1 (interquartile range (IQR) 8.2-20.3) months at time of data 
lock (480 active treatment years) (Table  1 ). In the dupilumab cohort, 
99.5% had a history of prior treatment with oral immunosuppressive 
drugs (93.8% CsA, 33.8% MTX, 22.9% azathioprine, 16.9% enter-
ic-coated mycophenolate sodium) compared to 19.4% in the CsA and 
69.7% in the MTX cohort. 
 At the moment of data lock, 358 patients (89%) used dupi-
lumab, 37 patients (9%) had discontinued dupilumab treatment, and 
  
 Dupilumab 
(n = 402) 
 Cyclosporine A 
(n = 356) 
 Methotrexate 
(n = 89) 
 Female, n (%)  157 (39.1)  167 (46.9)  36 (40.4) 
 Age (y), mean (±SD)  43.3 (15.8)  37.6 (14.2)  50.1 (17.3) 
 History of prior treatment with oral 
immunosuppressive drugs, n (%) 
 400 (99.5)  69 (19.4)  62 (69.7) 
 Treatment duration (mo), 
 a   median (IQR) 
 15.1 (8.2-20.3)  7.9 (3.2-14.4)  7.3 (3.0-11.4) 
 Status of use,  c n (%) 
 Active  358 (89.1)  80 (22.5)  37 (41.6) 
 Discontinued  37 (9.2)  258 (72.4)  45 (50.5) 
 Lost to follow-up  7 (1.7)  18 (5.1)  7 (7.9) 
 a Data lock two years after start treatment; dupilumab 15-12-2019; cyclosporine A 01-01-2014; 
methotrexate 01-02-2015.  
 TA B L E   1     Patient and treatment 
characteristics for treatment with 
dupilumab, cyclosporine A, and 
methotrexate 
 F I G U R E   1     A, Overall drug survival for dupilumab, cyclosporine 
A, and methotrexate. B, Drug survival related to discontinuation 
due to treatment failure for dupilumab, cyclosporine A, and 
methotrexate 
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7 patients (2%) were lost to follow-up. The most frequent reason 
for discontinuation of dupilumab was side effects (17 patients (4%)). 
Seven patients (2%) discontinued treatment because of ineffective-
ness, two patients (0.5%) due to a combination of both side effects 
and ineffectiveness (Table  S1 ). Regarding CsA, 356 patients were 
included with a median treatment duration of 7.9 (IQR 3.2-14.4) 
months. The majority of the patients (n = 258 (73%)) discontinued 
treatment within two years after start of CsA, mostly because of 
well-controlled disease (n = 79(22%)) followed by side effects (n = 72 
(20%)). 8 The MTX cohort included a total of 89 patients with a me-
dian treatment duration of 7.3 (IQR 3.0-11.4) months. Half of the 
patients (n = 45 (51%)) discontinued treatment after two years of fol-
low-up, 22 patients (25%) due to side effects, and 13 patients (15%) 
due to ineffectiveness. 7 
 The overall drug survival rates for dupilumab were 91% and 88% 
after 1 and 2 years, respectively. In CsA-treated patients, drug sur-
vival rates were 37% and 20%. This was comparable to the drug 
survival of MTX, which was 41% and 33%, after, respectively, 1 and 
2 years. Drug survival of dupilumab was significantly longer com-
pared to MTX and CsA ( P < .0001) (Figure  1A ). Approximately, half 
of the patients discontinued CsA and MTX because of treatment 
failure (ineffectiveness and/or side effects); limited dupilumab pa-
tients discontinued treatment due to treatment failure (Figure  1B ). 
Due to the low number of patients discontinuing dupilumab treat-
ment, a prediction analysis of drug survival was not possible in the 
present study. 
 A drug survival rate of 89% after 800 days (26.3 months) of 
treatment with dupilumab in a daily practice cohort (n = 112) of AD 
patients treated at a tertiary care center in the United States (US) 
was reported by Khosravi et al Reasons for discontinuation were 
AD flare (5/112 (5%)), conjunctivitis (3/112 (3%)), and adequate 
control with phototherapy (1/112 (1%)). 6 Overall drug survival rates 
were comparable with the results of our study, although we found 
a slightly lower rate of discontinuation due to ineffectiveness (2% 
vs 5%). 
 Drug survival is influenced by the availability of alternative treat-
ment options and changes in the population treated over time. None 
of patients were previously treated with dupilumab. Patients in-
cluded in the MTX and CsA cohort were treated before initiation of 
clinical trials and marketing authorization of dupilumab, and there-
fore, the availability of dupilumab did not influence the drug survival 
in these cohorts. Longer drug survival of dupilumab (compared to 
MTX and CsA) can be explained by a persistent clinical response and 
lack of discontinuation due to controlled disease, but also due to the 
lack of availability of alternative treatment options. 
 In conclusion, this study shows that dupilumab has a longer drug 
survival compared to CsA and MTX. Only a limited number of dup-
ilumab patients discontinued treatment due to side effects and/or 
ineffectiveness. Future daily practice data will provide further im-
portant information on the impact of the introduction of new bio-
logic agents and small molecules for the treatment of AD on drug 
survival of dupilumab. 
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 Association of rhinovirus species with nasopharyngeal 
metabolome in bronchiolitis infants: A multicenter study 
 To the Editor, 
 Bronchiolitis is the leading cause of hospitalization in US infants. 1 
The majority of severe bronchiolitis (requires hospitalization) is 
caused by respiratory syncytial virus (RSV) and rhinovirus (RV). 1 RVs 
are RNA viruses with >160 recognized genotypes that are classified 
into three species (A, B, and C). 2 While bronchiolitis is traditionally 
considered a single disease entity and currently available treatment 
does not differ by viral etiology, 1,3 recent studies suggest heteroge-
neity of bronchiolitis by infecting virus. 4 Indeed, research has shown 
that RSV and RV species are associated not only with different acute 
(eg, disease severity) 1 and chronic (eg, incident asthma) 5 morbidity 
burdens, but also with different airway microbiota profiles. 6 Despite 
the clinical and research importance, it remains unclear how different 
RV species perturb the downstream functional molecules that influ-
ence clinical phenotypes in infants with bronchiolitis. Metabolomics 
address this knowledge gap through comprehensively profiling me-
tabolites that are a function of the child ' s genetic architecture and 
environmental factors, 1 such as respiratory viruses. In this study, we 
investigated the relationships between respiratory viruses (includ-
ing different RV species) and nasopharyngeal metabolome in infants 
with severe bronchiolitis. 
 This is an analysis of data from the 35th Multicenter Airway 
Research Collaboration (MARC-35) cohort study—a multicenter pro-
spective cohort study of infants with severe bronchiolitis. The de-
tails of the study design, measurements, and analysis are described 
in the Online Supplement. Briefly, we enrolled 1016 infants (aged 
<1 year) hospitalized with bronchiolitis—according to the American 
Academy of Pediatrics guidelines 3 —in 17 sites across 14 US states 
(Table  S1 ). Investigators collected nasopharyngeal samples within 
24 hours of hospitalization using a standardized protocol. 7 These 
samples underwent (a) real-time PCR to test for respiratory viruses, 
with subsequent RV genotyping at the University of Wisconsin—
Madison, and (b) liquid chromatography-tandem mass spectrome-
try to profile the metabolome. In the current analysis, we grouped 
infants into three mutually exclusive virus categories: RSV-only 
(reference), RV-A, and RV-C. In the primary analysis, we excluded 
RV-B infection because of its clinical insignificance 1 and fewer num-
ber of cases. We compared the detected metabolites between RSV 
and RV-A as well as between RSV and RV-C groups. To account for 
high-order nonlinear correlations between metabolites, we fit ran-
dom forest models and determined 30 metabolites with largest 
between-group difference for the downstream analyses. We then 
tested for the association of viruses with each metabolite level by 
fitting multivariable linear regression models with multiple test ad-
justment. Next, using graphical modeling approach, we inferred the 
underlying relationship between respiratory viruses, patient ' s age, 
corticosteroid use, and metabolites from the cross-sectional data. 
To detect biologically meaningful pathways, we also performed a 
pathway analysis (metabolite set enrichment analyses). Lastly, we fit 
multivariable logistic regression models to examine the association 
 DOI: 10.1111/all.14326 
